Effects on metabolic variables after 12-month treatment with a new once-a-week sustained-release recombinant growth hormone (GH: LB03002) in patients with GH deficiency.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

As a substudy to the phase III study, the researchers performed this prospective study to evaluate the influence of LB03002 on metabolic variables and hormones.

Who Took Part

According to the abstract, 12 patients were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Eleven patients with GHD [four women/seven men, 58 years (29-69 years)] without GH therapy were included in the study.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

A 3-h oral glucose tolerance test (OGTT) was performed at study entry and at study end.

Additionally, IGF-I, cholesterol, LDL, HDL, triglycerides, leptin, ghrelin, HbA1c and C-peptide were measured.

Body composition was evaluated by dual-energy X-ray absorptiometry (DXA), and waist/hip ratio (WHR) and waist/height (WHtR) ratio were measured by tape and scale.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Composition, Ghrelin, Glucose Tolerance Test, Growth Hormone, Insulin and Insulin Resistance.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.